Presenilins, β-amyloid precursor protein and the molecular basis of Alzheimer's disease

Clinical Neuroscience Research

Volumn 1, Issue 1-2, 2001, Pages 91-103

  Selkoe, Dennis J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Genetics; Neuropathology; Presenilin; Therapeutics

Indexed keywords

EID: 0002052826     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(00)00016-5     Document Type: Article

References (94)

1. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984;122:1131-1135.
2. Kang J, Lemaire H-G, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736.
3. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Harigaya Y. Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol 1988;77:113-119.
4. Tagliavini F, Giaccone G, Frangione B, Bugiani O. Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett 1988;93:191-196.
5. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina H, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53.
6. Cummings BJ, Pike CJ, Shankle R, Cotman CW. β-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Ageing 1996;17:921-933.
7. Selkoe DJ. Preface. In: Verbeek MM, de Wall RMV, Vinters HV, editors. Cerebral Amyloid Angiopathy in Alzheimer's disease and related disorders, Dordrecht, The Netherlands: Kleuwer, 2000. pp. 357.
8. Goedert M, Trojanowski JQ, Lee VM-Y, et al. The neurofibrillary pathology of Alzheimer's disease. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, editors. The molecular and genetic basis of neurological disease, 2nd Ed. 1996. pp. 613-627.
9. Nukina N, Ihara Y. One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem 1986;99:1541-1544.
10. Grundke-Iqbal I, Iqbal K, Tung Y-C, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein t (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913-4917.
11. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein, tau, is a major antigenic component of paired helical filaments in Alzheimer's disease, Proc Natl Acad Sci USA 1986;83: 4044-4048.
12. Terry RD, Hansen LA, DeTeresa R, Davies P, Tobias H, Katzman R. Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropath Exp Neurol 1987;46:262-268.
13. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
14. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
15. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399:A23-A31.
16. Zheng H, Jiang M, Trumbauer ME, et al. β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995;81:525-531.
17. Perez RG, Zheng H, Van der Ploeg LH, Koo EH. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci 1997;17:9407-9414.
18. Wasco W, Bupp K, Magendantz M, Gusella J, Tanzi RE, Solomon F. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid β-protein precursor. Proc Natl Acad Sci USA 1992;89:10758-10762.
19. Slunt HH, Thinakaran G, Von Koch C, Lo ACY, Tanzi RE, Sisodia SS. Expression of a ubiquitous, cross-reactive homologue of the mouse β-amyloid precursor protein (APP). J Biol Chem 1994;269:2637-2644.
20. Haass C, Schlossmacher M, Hung AY, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322-325.
21. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992;258:126-129.
22. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantitation of soluble Alzheimer's β-peptide from biological fluids. Nature 1992;359:325-327.
23. Sisodia SS. β-Amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 1992;89:6075-6079.
24. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733.
25. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998;273:27765-27767.
26. Seubert P, Oltersdorf T, Lee MG, et al. Secretion of β-amyloid precursor protein cleaved at the amino-terminus of the β-amyloid peptide. Nature 1993;361:260-263.
27. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-741.
28. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402:537-540.
29. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999;402:533-537.
30. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
31. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
32. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer disease. Nature 1995;375:754-760.
33. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-977.
34. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376:775-778.
35. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998;19:357-360.
36. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998;95:7737-7741.
37. Hutton M, Lendon C, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited FTDP-17. Nature 1998;393:702-705.
38. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998;282:1914-1917.
39. Goedert M. Tau mutations cause frontotemporal dementias. Neuron 1998;21:955-958.
40. Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels of amyloid beta proteins Abetal-40 and Abetal-42(43) are elevated in Down's syndrome. Ann Neurol 1997;41:271-273.
41. Lemere CA, Blustzjan JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996;3:16-32.
42. Mann DM, Iwatsubo T, Fukumoto H, Ihara Y, Odaka A, Suzuki N. Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. Acta Neuropathol (Berl) 1995;90:472-477.
43. Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage. Dutch-type, Science 1990;248:1124-1126.
44. Hendriks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat Genet 1992;1:218-221.
45. Haass C, Hung AY, Selkoe DJ, Teplow DB. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid β-protein precursor. J Biol Chem 1994;269:17741-17748.
46. Biere AL, Ostaszewski B, Zhao H, Gillespie S, Younkin SG, Selkoe DJ. Co-expression of β-amyloid precursor protein (βAPP) and apolipoprotein E in cell culture: analysis of βAPP processing. Neurobiol Dis 1995;2:177-187.
47. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
48. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E, in sporadic Alzheimer's disease: allelic variation and receptor inter-actions. Neuron 1993;11:575-580.
49. Ma J, Yee A, Brewer Jr. HB, Das S, Potter H. The amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote the assembly of the Alzheimer β-protein into filaments. Nature 1994;372:92-94.
50. Evans KC, Berger EP, Cho C-G, Weisgraber KH, Lansbury Jr PT. Apolipoprotein E, is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA 1995;92:763-767.
51. Bales KR, Verina T, Dodel RC, et al. Lack of apolipprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 1997;17:263-264.
52. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870.
53. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100.
54. Lemere CA, Lopera F, Kosik KS, et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med 1996;2:1146-1150.
55. Mann DMA, Iwatsubo T, Cairns NJ, et al. Amyloid beta protein (A-beta) deposition in chromosome 14-linked Alzheimer's disease - predominance of A-beta (42(43)). Ann Neurol 1996;40:149-156.
56. Ray WJ, Yao M, Nowotny P, et al. Evidence for a physical interaction between presenilin and Notch. Proc Natl Acad Sci USA 1999;96:3263-3268.
57. Levitan D, Doyle TG, Brousseau D, et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci USA 1996;93:14940-14944.
58. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398:518-522.
59. Selkoe DJ. Notch and presenilins in vertebrates and invertebrates: implications for neuronal development and degeneration. Curr Opin Neurobiol 2000;10:50-57.
60. Wong P, Zhen H, Chen H, et al. Presenilin 1 is required for Notch 1 and Dill expression in the paraxial mesoderm. Nature 1997;397:288.
61. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in presnilin-1 deficient mice. Cell 1997;89:629-639.
62. Thinakaran G, Borchelt DR, Lee MK, et al. Endoprotreolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 1996;17:181-190.
63. Thinakaran G, Regard JB, Bouton CML, et al. Stable association of presenilin derivatives and absence of presenilin interactions with APP. Neurobiol Dis 1998;4:438-453.
64. Naruse S, Thinakaran G, Luo JJ, et al. Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron 1998;21:1213-1221.
65. Weidemann A, Paliga K, Durrwang U, et al. Formation of stable complexes between two Alzheimer's disease gene products: Presenilin-2 and β-amyloid precursor protein. Nat Med 1997;3:328-332.
66. Xia W, Zhang J, Perez R, Koo EH, Selkoe DJ. Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer's disease. Proc Natl Acad Sci USA 1997;94:8208-8213.
67. Xia W, Zhang J, Ostaszewski BL, et al. Presenilin 1 regulates the processing APP C-terminal fragments and the generation of amyloid β-protein in ER and Golgi. Biochemistry 1998;37:16465-16471.
68. Kimberly WT, Xia W, Rahmati R, Wolfe MS, Selkoe DJ. The transmembrane aspartates in presenilin 1 and 2 are obligatory for γ-secretase activity and amyloid β-protein generation. J Biol Chem 2000;275:3173-3178.
69. Wolfe MS, Xia W, Moore CL, et al. Peptidomimetic probes and molecular modeling suggest Alzheimer's γ-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry 1999;38:4720-4727.
70. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 1999;398:513-517.
71. Brockhaus M, Grunberg J, Rohrig S, et al. Caspasse-mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling. NeuroReport 1998;9:1481-1486.
72. Skovronsky DM, Doms RW, Lee VM-Y. Detection of a novel intraneuronal pool of insoluble amyloid α protein that accumulates with time in culture. J Cell Biol 1998;141:1031-1039.
73. Walsh, DM, Tseng, BP, Rydel, RE, Podlisny, MB, Selkoe, DJ, Detection of intracellular oligomers of amyloid β-protein in cells derived from human brain, 2000;39:10831-10839.
74. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfribrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins, Proc Natl Acad Sci USA 1998;95:6448-6453.
75. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994;15:447-450.
76. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
77. Rogers J, Webster S, Leu FL, et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996;17:681-686.
78. Rogers J, Cooper NR, Websger S, et al. Complement activation by β-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992;89:10016-10020.
79. Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res 1994;645:78-84.
80. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994;77:817-827.
81. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol 1995;131:193-202.
82. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-1222.
83. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:379-389.
84. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993;13:1676-1687.
85. Lorenzo A, Yankner B. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 1994;91:12243-12247.
86. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615-622.
87. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;373:523-527.
88. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
89. Sturchler-Pierrat C, Abrahamowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997;94:13287-13292.
90. Gouras GK, Tasi J, Naslund J, et al. Intraneuronal Aβ42 accumulation in human brain. Am J Pathol 2000;156:15-20.
91. Wolozin B, Iwasaki K, Vito P, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996;274:1710-1713.
92. Siman R, Reaume A, Savage MJ, Scott RW, Flood DG. Presenilin 1 P264L knock-in mutation: effect on cortical neuronal vulnerability to degeneration. J Neurosci Abstr 1999;25(Pt 1):1046(426.5).
93. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998;393:382-386.
94. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.